Search

Background: Diabetic foot ulcers (DFU) pose a significant health risk in diabetic patients, with insufficient revascularization during wound healing being the primary cause. This study aimed to assess microvessel sprouting and wound healing capabilities using vascular endothelial growth factor (VEGF-A) and a modified fibroblast growth factor (FGF1). Methods: An ex vivo aortic ring rodent model and an in vivo wound healing model in diabetic mice were employed to evaluate the microvessel sprouting and wound healing capabilities of VEGF-A and a modified FGF1 both as monotherapies and in combination. Results: The combination of VEGF-A and FGF1 demonstrated increased vascular sprouting in the ex vivo mouse aortic ring model, and topical administration of a combination of VEGF-A and FGF1 mRNAs formulated in lipid nanoparticles (LNPs) in mouse skin wounds promoted faster wound closure and increased neovascularization seven days post-surgical wound creation. RNA-sequencing analysis of skin samples at day three post-wound creation revealed a strong transcriptional response of the wound healing process, with the combined treatment showing significant enrichment of genes linked to skin growth. Conclusion: f-LNPs encapsulating VEGF-A and FGF1 mRNAs present a promising approach to improving the scarring process in DFU., CC BY 4.0 DEED© 2024 by the authors.Correspondence Address: S. Tejedor; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, 431 50, Sweden; email: sandra.tejedorgascon1@astrazeneca.com; K. Hansson; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, 431 50, Sweden; email: kenny.m.hansson@astrazeneca.comThis research was partially funded by grants from the Swedish Knowledge Foundation, grant number 20200014.

Decentralized autonomous organizations (DAOs) have emerged as a novel governance mechanism that operates through distributed ledgers and smart contracts, enabling members to direct an organization's actions. The widespread adoption of DAOs has occurred in response to their utility in managing emergent semi‐structured projects and has led to the development of various innovative governance mechanisms. The mechanisms employed by DAOs has the potential to be generalized beyond their core financial domain to a wide range of use cases. In the medical field the use of blockchain and DAOs can provide secure and transparent access to medical data, while ensuring patient privacy. Civic access to medical data is a growing area of interest, where individuals have control over their own medical data and can share it with healthcare providers, researchers, and other stakeholders. DAOs can facilitate this civic access, enabling individuals to share their data securely and selectively with authorized parties for research and other purposes. This paper explores the use of DAOs to medical data sharing, with a focus on ownership, governance, and transaction models. An application framework and API that enables the deployment of DAO‐like organizations is derived and this approach is applied to the patient‐centric management of medical data.